GENMAB A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 261.2 EUR | -21.10% |
|
0.00% | 0.00% |
| 11:54am | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
| 06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.89B 2.65B 226B | Sales 2025 * | 23.62B 3.45B 3.16B 269B | Capitalization | 126B 18.31B 16.81B 1,432B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 683M 627M 53.4B | Net income 2025 * | 6.61B 965M 886M 75.44B | EV / Sales 2024 * | 5.03 x |
| Net cash position 2024 * | 25.92B 3.78B 3.47B 296B | Net cash position 2025 * | 32.36B 4.72B 4.34B 369B | EV / Sales 2025 * | 3.94 x |
| P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
20.6
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -21.10% |
3 years
283.00
353.50
5 years
283.00353.50
10 years
283.00353.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,954
DKK
Average target price
2,464
DKK
Spread / Average Target
+26.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.72% | 121B | |
| +13.37% | 107B | |
| -5.26% | 24.82B | |
| +1.69% | 22.48B | |
| -40.52% | 16.33B | |
| -14.56% | 15.31B | |
| +3.34% | 14.08B | |
| +24.54% | 11.74B | |
| +83.62% | 9.02B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock
